Glaucoma scales fail to impress

Article

The Visual Impairment Instrument (IVI) and the Glaucoma Symptom Scale (GSS) are suboptimal scales for assessing patients with glaucoma but relatively good vision.

The Visual Impairment Instrument (IVI) and the Glaucoma Symptom Scale (GSS) are suboptimal scales for assessing patients with glaucoma but relatively good vision, according to a report published in the August issue of Optometry & Vision Science.

Ecosse Lamoureux and colleagues from the University of Melbourne, Australia recruited glaucoma patients from private and public clinics to complete the IVI and GSS questionnaires. The two scales were assessed for fit to the Rasch model; specifically they were assessed for unidimensionality, individual item and person fit to the model, response category performance, differential item functioning and targeting of items to patients.

A total of 175 subjects were recruited, the majority of whom (65%) had primary open-angle glaucoma (POAG) and a visual acuity ≥6/9 in the better eye (87%). Only one third of the subjects had severe visual field loss in both eyes. Disordered thresholds were evident across all GSS items, indicating that the categories were difficult to discriminate and required category collapsing (five to three categories). Both scales demonstrated ineffective person-item targeting.

The authors believe that both IVI and GSS are ineffective scales for assessing glaucomatous patients who have good visual acuity.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.